As part of a collaboration with Freenome, Institut Curie will look for correlations between circulating biomarkers and human response to cancer immunotherapies.
The latest version of the nucleic acid detection platform uses three CRISPR enzymes, making it more sensitive and capable of smaller quantitative measurements.
The company expects to be able to offer at least one test commercially by the end of this year or early next, with research now starting on two others.
The companies will combine Empire's NGS services and FISH probe portfolio with Kromatid's Pinpoint probes and directional genomic hybridization technology.
The collaborators have signed a two-year research and license option agreement to develop novel T-cell therapies for cancer using genome editing technology.
The Associated Press reports that an ethicist predicts that prenatal diagnosis and other advances will lead to more choices being available to prospective parents.
